Trial | NCT00450775  Report issue

Official Title

Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Indication/Condition

    Scars

  • Intervention/Treatment

    silicone ...

  • Study Participants

    12
The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.
Study Started
Mar 31
2007
Primary Completion
Mar 31
2008
Study Completion
Mar 31
2008
Last Update
Sep 25
2008
Estimate

Drug Dermatix Q

Dermatix Q applied twice daily

1 Other

Criteria 

Inclusion Criteria:

Female or male patients at least 18 years of age
Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc)
Able and willing to provide informed consent and likely to complete all study visits
All Fitzpatrick skin types will be evaluated

Exclusion Criteria:

Known contraindications to Dermatix or any of its components
Age of scar is > 4 months
Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)
No Results Posted